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SAHA overcomes FLIP-mediated inhibition of SMAC
mimetic-induced apoptosis in mesothelioma
N Crawford1, I Stasik1, C Holohan1, J Majkut1, M McGrath1, PG Johnston1, G Chessari2, GA Ward2, DJ Waugh1, DA Fennell3
and DB Longley*,1
Malignant pleural mesothelioma (MPM) is a highly pro-inflammatory malignancy that is rapidly fatal and increasing in incidence.
Cytokine signaling within the pro-inflammatory tumor microenvironment makes a critical contribution to the development of
MPM and its resistance to conventional chemotherapy approaches. SMAC mimetic compounds (SMCs) are a promising class of
anticancer drug that are dependent on tumor necrosis factor alpha (TNFa) signaling for their activity. As circulating TNFa
expression is significantly elevated in MPM patients, we examined the sensitivity of MPM cell line models to SMCs. Surprisingly,
all MPM cell lines assessed were highly resistant to SMCs either alone or when incubated in the presence of clinically relevant
levels of TNFa. Further analyses revealed that MPM cells were sensitized to SMC-induced apoptosis by siRNA-mediated
downregulation of the caspase 8 inhibitor FLIP, an antiapoptotic protein overexpressed in several cancer types including MPM.
We have previously reported that FLIP expression is potently downregulated in MPM cells in response to the histone deacetylase
inhibitor (HDACi) Vorinostat (SAHA). In this study, we demonstrate that SAHA sensitizes MPM cells to SMCs in a manner
dependent on its ability to downregulate FLIP. Although treatment with SMC in the presence of TNFa promoted interaction
between caspase 8 and the necrosis-promoting RIPK1, the cell death induced by combined treatment with SAHA and SMC was
apoptotic and mediated by caspase 8. These results indicate that FLIP is a major inhibitor of SMC-mediated apoptosis in MPM,
but that this inhibition can be overcome by the HDACi SAHA.
Cell Death and Disease (2013) 4, e733; doi:10.1038/cddis.2013.258; published online 18 July 2013
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Malignant pleural mesothelioma (MPM) is a pro-inflammatory
cancer associated with exposure to asbestos, which is
rapidly fatal and is increasing in incidence.1 High levels of
pro-inflammatory cytokines associated with asbestos
exposure have been linked to the initiation and progression
of MPM.2,3 Tumor necrosis factor alpha (TNFa) has been
described as an early biomarker for MPM following exposure
to asbestos. Circulating levels of TNFa are elevated in
patients with MPM, and these levels are reduced following
surgical debulking.4,5
The majority of MPM patients present in the advanced
stages where cisplatin and pemetrexed are the standard-
of-care chemotherapeutic agents, however, this combination
therapy only modestly increases survival rates. Patients
quickly relapse, and currently there is no standard-of-care
treatment in the second line setting. Drug resistance is amajor
hurdle in the treatment of MPM.6,7 Evasion of apoptosis is
evident in many cancers, includingmesothelioma, through the
high expression of inhibitor of apoptosis proteins (IAPs).8–10
High expression of cIAPs inMPMmodelsmediates resistance
to chemotherapy and correlates with poor prognosis in
patients.4
The defining features of cIAP1, cIAP2 and XIAP are their
three baculovirus IAP repeat (BIR) domains and their RING
zinc-finger domains.11,12 The BIR domains are important for
mediating protein–protein interactions, and the RING domain
possesses E3 ubiquitin ligase activity. XIAP is the only IAP
that directly inhibits caspases: XIAP binds to caspases 3 and
7 via the region between its BIR1 and BIR2 domains and via
the BIR2 domain itself, thereby directly inhibiting caspase
activity. In addition, the BIR3 domain of XIAP can bind to and
prevent homodimerization of caspase 9, thereby preventing
its activation. There is also evidence that XIAP may target
caspases for ubiquitination and degradation by the
proteasome via its RING domain.13–15
The roles of cIAP1 and cIAP2 aremore complex and involve
regulation of signaling via TNF receptor 1 (TNFR1).16,17
Following binding of the pro-inflammatory cytokine TNFa,
TNFR1 recruits an adapter protein TRADD (TNFR-associated
death domain) and receptor-interacting protein kinase 1
(RIPK1). TRADD recruits TRAF2 (TNFR-associated
factor 2), and cIAP1 and cIAP2 to form a large membrane
complex. At this complex (termed complex I), cIAP1 and
cIAP2 act as E3 ubiquitin ligases adding lysine 63 (K63)-
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linked polyubiquitin chains to RIPK1. Polyubiquitinated RIPK1
then serves as a docking site for the downstream kinases that
activate the canonical nuclear factor-kB (NF-kB, RelA/p50)
signaling pathway. In the absence of cIAP1/2, RIPK1 is not
polyubiquitinated and forms a second complex (complex IIb),
which recruits Fas-associated via death domain (FADD),
caspase 8 and FLIP.18 Thus, by ubiquitinating RIPK1, cIAP1
and cIAP2 act as positive regulators of the generally
antiapoptotic, pro-inflammatory canonical NF-kB signaling
pathway and at the same time inhibit caspase 8 activation in
response to ligation of TNFR1. Complex I can dissociate to
form Complex IIa, a death inducing complex similar to
Complex IIb, which is composed of TRADD, FADD, caspase
8 and FLIP.19 FLIP is an antiapoptotic caspase 8 paralog,
which prevents Complexes IIa and IIb from initiating apoptosis.
Moreover, FLIP is the product of an NFkB target gene
(CFLAR) and therefore is upregulated following TNFR1
ligation.20 FLIP is mainly expressed as two splice forms: a long
form FLIP(L) and a short form FLIP(S). FLIP inhibits apoptosis
through binding to FADD and blocking caspase 8 activation
in Complex IIa and IIb. Under certain conditions Complex II
can induce cell death through an non-apoptotic,
programmed necrosis pathway, which is dependent on RIPK1
and 3.21
IAPs are recognized as attractive targets for anticancer
therapeutics. Cellular IAP 1 (cIAP1), cIAP2 and X-linked IAP
(XIAP) are the cellular targets for SMAC mimetic compounds
(SMCs), which mimic the functions of the endogenous IAP
antagonist SMAC. Second mitochondrial derived activator of
caspases (SMAC) is released from the mitochondria by
various stimuli and promotes apoptosis through its ability
to antagonize IAP-mediated caspase inhibition.22 SMCs bind
to BIR2 and three domains of XIAP and neutralize its inhibition
of caspases 3 and 7. SMCs also bind cIAP1 and cIAP2,
resulting in a conformational change that leads to RING
dimerization and activation of their E3 ligase activity, resulting
in their rapid autoubiquitination and degradation.23,24 As
ligation of TNFR1 by TNFa in the absence of cIAP1 and
cIAP2 rapidly leads to formation of the cell death inducing
complex IIb,25 we hypothesized that the high levels of TNFa
associated with mesothelioma would make this disease
particularly vulnerable to SMCs. We therefore investigated
whether SMC-mediated inhibition of IAPs could use extra-
cellular TNFa to drive apoptosis in mesothelioma.
Results
Effects of AT-IAP on cIAP and FLIP expression in
MPM. To model the impact of SMCs in mesothelioma, we
selected four MPM cell line models with different levels of
cIAP1, cIAP2 and XIAP expression (Figure 1a). These cell
line models also differed in their expression levels of FLIP(L),
FLIP(S) and FADD, although expression of RIPK1 and
procaspase eight were similar across the panel. Of note,
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Figure 1 (a) Western blot analysis of cIAP1, cIAP2, XIAP, FLIP(L), FLIP(S), procaspase 8, FADD and RIPK1 expression in a panel of MPM cell lines. (b) TNFR1 cell
surface expression in a panel of MPM cell lines expressed as % positive cells compared with an IgG isotype control. (c) Western blot analysis of cIAP1, cIAP2, XIAP, FLIP(S),
FLIP(L) and procaspase 8 following treatment with 10 mM AT-IAP for 1, 3, 6, 10 and 24 h in the REN cell line. (d) Quantitative RT-PCR assessment of TNFa, FLIP(S), FLIP(L),
cIAP1 and cIAP2 mRNA expression in REN cells following treatment with 10 mM AT-IAP for 10 h. Expression levels are reported relative to b-actin expression. Experimental
results were compared using a two-tailed Students t-test, ***Po0.001. Experiments were carried out in triplicate. (e) Western blot analysis of cIAP1 expression following
treatment of the REN cell line with 10 mM, 1 mM, 0.1mM, 10 nM and 1 nM AT-IAP for 24 h
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TNFa was undetectable in the culture medium of these cell
lines under basal conditions and following treatment with
SMCs (data not shown). The MPM cell lines also expressed
TNFR1 on the cell surface to varying levels (Figure 1b).
In this study, we used a novel SMC (AT-IAP) from
Astex Pharmaceuticals that is a monovalent inhibitor
with nanomolar affinity for the BIR3 domain of both XIAP
and cIAP1 (Supplementary Figure 1A).26 AT-IAP also
induces apoptosis in the breast cancer cell lines EVSA-T
and MDA-MB-231, which are sensitive to cIAP1 inhibition
(Supplementary Figure 1B). Expression levels of FLIP are
lower in MDA-MB-231 cells compared with a panel of
mesothelioma cells (Supplementary Figure 1C).
Consistent with the expected pharmacodynamic effects of a
SMC, treatment of MPM cells with AT-IAP downregulated
cIAP1 and cIAP2 expression within 1 h of treatment
(Figure 1c and Supplementary Figure 2A). Moreover, cIAP2
mRNA (Figure 1d and Supplementary Figure 2B) and protein
expression (Figure 1c and Supplementary Figure 2A) recov-
ered rapidly following treatment with AT-IAP, consistent with
the expected activation of the non-canonical NIK-dependent
NFkB pathway following treatment with a SMC.27 Although
cIAP1 mRNA increased in response to AT-IAP (Figure 1d
and Supplementary Figure 2B), its protein expression
remained suppressed (Figure 1c and Supplementary
Figure 2A). Increased mRNA expression of the NFkB target
gene encoding TNFa was also observed (Figure 1d and
Supplementary Figure 2B), as was increased mRNA
(Figure 1d and Supplementary Figure 2B) and protein
expression (Figure 1c and Supplementary Figure 2A) of the
caspase 8 inhibitor and NFkB target gene, FLIP. Furthermore,
treatment with concentrations of AT-IAP as low as 10 nM
induced cIAP1 downregulation, demonstrating the high
on-target potency of this agent (Figure 1e and
Supplementary Figure 2C).
MPM cell lines are insensitive to AT-IAP. To assess the
sensitivity of MPM cells to AT-IAP, we conducted cell viability
assays in the presence and absence of cotreatment with a
physiologically relevant concentration of TNFa (10 ng/ml) in
order to mimic the pro-inflammatory micro-environment
of mesothelioma.4 Surprisingly, none of the MPM cell lines
were sensitive to AT-IAP at concentrations up to 10 mM,
either alone, or in cells cocultured with TNFa (Figure 2a).
Similar results were obtained with several other SMCs
(data not shown). To determine whether high expression
of IAPs was responsible for resistance to AT-IAP, we used
siRNA to individually downregulate cIAP1, cIAP2 and XIAP
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Figure 2 (a) Cell viability assays in (i) REN, (ii) MM98, (iii) H28 and (iv) JU77 cell lines following treatment with 100mM, 10mM and 1mM AT-IAP either alone or in
combination with 10 ng/ml TNFa for 72 h. (b) Cell viability assays in (i) REN, (ii) MM98, (iii) H28 and (iv) JU77 cells transfected with 10 nM SCR, XIAP (XIAPsi), cIAP1(cIAP1si)
or cIAP2 (cIAP2si) for 24 h before treatment with 10 mM AT-IAP wither alone or in combination with 10 ng/ml for a further 48 h (knockdown of target proteins by the individual
siRNAs is shown in Supplementary Figure 3A). Experimental results were compared using a two-tailed Student’s t-test, *Po0.05 and **Po0.01. Experiments were carried
out in triplicate
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(Supplementary Figure 3A). In Ren cells cocultured
with TNFa, downregulation of cIAP1 and to a lesser extent
XIAP and cIAP2 moderately increased sensitivity to
AT-IAP (Figure 2b); however, none of the other cell lines
was sensitized to AT-IAP following siRNA-mediated
IAP depletion, suggesting that high IAP expression is not
responsible for resistance in these models.
FLIP regulates sensitivity to AT-IAP in MPM. SMCs are
known to promote formation of TNFR complex IIa and b and
the ripoptosome,28–30 all of which are potentially activating
platforms for the initiator caspase, procaspase 8. However,
dimerization of procaspase 8 (a prerequisite for its activation)
at these complexes can be inhibited by FLIP. Indeed, we
found that caspase 8 and FLIP interacted in MPM cells
following treatment with AT-IAP and TNFa and moreover,
FLIP(L) was recovered in its p43-form indicative of its
dimerization with and processing by procaspase 8 at TNFR
complex IIb31 (Figure 3a). Of note, RIPK1 also interacted
with caspase 8 in AT-IAP/TNFa-treated cells (Figure 3a), but
not in cells treated with AT-IAP alone or TNFa alone
(Supplementary Figure 4A). Further evidence that this
caspase 8/RIPK1 complex is complex IIb was obtained in
cells in which the critical adapter protein for this complex
FADD was silenced, as FADD downregulation abrogated the
interaction between caspase 8 and RIPK1 (Supplementary
Figure 4B).
To assess whether FLIP expression in MPM cells is
responsible for their resistance to SMCs, we downregulated
FLIP expression with siRNA and assessed sensitivity to
AT-IAP in the presence and absence of TNFa A FLIP(L) and
FLIP(S) dual-targeted siRNA and splice form-specific siRNAs
were used (Figure 3b and Supplementary Figure 3B). The cell
lines exhibited different levels of sensitivity to FLIP depletion
alone as assessed in cell viability experiments, with Ren and
H28 cells sensitive to loss of either splice form, MM98 cells
sensitive to simultaneous downregulation of both splice forms
and Ju77 insensitive to FLIP depletion alone (Figure 3c).
In Ren cells cocultured with TNFa, downregulation of either
splice form increased cell death in response to AT-IAP,
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Figure 3 (a) Western blot analysis of c-FLIP, RIPK1 and caspase 8 following caspase 8 immunoprecipitation in MM98 cells treated with a combination of 10mM AT-IAP
and 10 ng/ml TNFa for 6 h in the presence of 10mM z-VAD-fmk. An IgG-matched isotype control was used as control. (b) Western blot analysis of c-FLIP expression in
REN cells following 48 h treatment with SCR siRNA (SCR), siRNA specifically targeting FLIP short (FLIP(S)si) and FLIP long (FLIP(L)si) and siRNA targeting total
FLIP (FLIP(T)si). (c) Cell viability assays following transfection of (i) REN, (ii) MM98, (iii) H28 and (iv) JU77 cells with SCR, FLIP(S), FLIP(L) and FLIP(T) siRNA and treatment
with 10mM AT-IAP, 10 ng/ml TNFa and combination of AT-IAP and TNFa for 48 h
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although the most potent effects were observed when
both splice forms were simultaneously downregulated
(Figure 3c(i)). Similar results were obtained in MM98 cells
(Figure 3c(ii)). In H28 and JU77 MPM cells, downregulation of
FLIP(S) failed to enhance AT-IAP/TNFa-induced cell death,
whereas FLIP(L) downregulation significantly enhanced cell
death (Figure 3ciii and iv). These differences between the
cell lines may be related to their relative levels of FLIP(L) and
FLIP(S) expression, as well as different levels of expression
of other components of the TNFR1 signaling pathway
(Figure 1a).
Consistent with these findings, siRNA-mediated down-
regulation of either FLIP(L) or FLIP(S) enhanced caspase 3
processing and PARP cleavage in AT-IAP/TNFa-treated
MPM Ren cells, although maximal levels of PARP cleavage
were observed when both splice forms were simultaneously
downregulated (Figure 4a). Also of note, treatment with TNFa
alone induced PARP cleavage when either FLIP(S) or FLIP(L)
were silenced and particularly when both splice forms were
silenced, consistent with FLIP acting as an inhibitor of TNFR1
complex II-induced apoptosis. Somewhat surprisingly, down-
regulating FLIP did not significantly enhance apoptosis
induced by AT-IAP alone (Figures 3c and 4a), suggesting
that this combination treatment is not sufficient to drive
complex IIb formation. Indeed, we found that FLIP silencing
did not promote formation of complex IIb formation either
in response to SMC or TNFa treatment (Supplementary
Figure 4C). FLIP(L) but not FLIP(S) silencing significantly
enhanced apoptosis in Ju77 MPM cells as assessed by flow
cytometry, with maximal levels of apoptosis induced when
both splice forms were downregulated (Figure 4b). AT-IAP in
combination with TNFa in REN, MM98, JU77 and H28 cells
efficiently activated caspase 8 (Supplementary Figure 5A)
and caspase 3/7 (Supplementary Figure 5B) following FLIP
silencing (Supplementary Figure 5C).
To further prove that it is FLIP’s recruitment to complex IIb
that modulates sensitivity to AT-IAP/TNFa, we utilized a
FLIP mutant (F114A) that cannot interact with the critical
adapter protein in the complex, FADD32 (Figure 4c). When
endogenous FLIP(L) and FLIP(S) proteins were depleted with
a 50-UTR-targeting siRNA (Supplementary Figure 4D), an
exogenously expressed wild-type FLIP(S) protein was able to
completely rescue the cell death induced by AT-IAP/TNFa
treatment, however, the exogenously expressed F114A
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Figure 4 (a) Western blot analysis of PARP cleavage and caspase 3 activation in REN cells following transfection with SCR, FLIP(S), FLIP(L) and FLIP(T) siRNA. Cells
were treated with 10mM AT-IAP, 10 ng/ml TNFa and a combination of AT-IAP and TNFa for 24 h. (b) (i) Western blot analysis of c-FLIP in JU77 cells transfected with SCR,
FLIP(S), FLIP(L) and FLIP(T) siRNA for 48 h. (ii) Flow cytometry determination of sub G0/G1 apoptotic populations of JU77 cells following transfection with SCR, FLIP(S),
FLIP(L) and FLIP(T) siRNA and treatment with 10mM AT-IAP, 10 ng/ml TNFa and a combination of AT-IAP and TNFa for 24 h. (c) AlphaScreen assay of protein/protein
interaction between recombinant GST-tagged FADD and FLAG-tagged wild-type (WT) and F114A mutant FLIP(S) proteins. (d) Cell viability assays in control (EV), wild-type
(WT) and F114A mutant FLIP(S) overexpressing cell lines following transfection with SCR siRNA or an siRNA targeting the common 50-UTR of the FLIP(L) and FLIP(S)
transcripts (50UTR FLIP(T)) for 24 h followed by treatment with 10 mM AT-IAP, 10 ng/ml TNFa and a combination of AT-IAP and TNFa for 48 h
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FLIP(S) mutant failed to rescue the cell death phenotype
(Figure 4d), indicating that FLIP(S) must be able to interact
with FADD to inhibit cell death induced by AT-IAP/TNFa.
Interaction between cisplatin and AT-IAP. Cisplatin is one
of the standard-of-care chemotherapeutic drugs used to
treat mesothelioma and has been previously shown to
downregulate FLIP(L) and FLIP(S) expression in several
cancers.33,34 Treatment of MPM cell lines with cisplatin
resulted in significant (44-fold) downregulation of FLIP(S) in
REN and MM98 cell lines after treatment with 5 mM drug for
48 h, whereas a more modest (B2-fold) downregulation of
FLIP(S) was observed in Ju77 and H28 cells and only after
treatment with 10 mM cisplatin (Figure 5a). Overall however,
the effects of cisplatin treatment on FLIP(L) expression were
modest, with significant (42-fold) downregulation only
observed in response to 10 mM cisplatin in Ren cells. Notably,
in the two cell lines in which FLIP expression was most
downregulated in response to cisplatin, Ren and MM98,
significant synergy was observed between cisplatin and
AT-IAP in the presence of cotreatment with TNFa
(Figure 5b). In H28 and Ju77 cells, the interaction of cisplatin
with AT-IAP was less effective at reducing cell viability, with a
greater-than-additive effect only observed when cells were
treated with 10 mM cisplatin. Thus, increased sensitivity to
AT-IAP and TNFa in these mesothelioma models correlated
with extent of FLIP downregulation in response to cisplatin
(Figures 5a and b). However, these results demonstrate
that although cisplatin can induce downregulation of FLIP(S)
in some MPM cell lines, it has little effect on FLIP(L)
expression.
The HDAC inhibitor SAHA downregulates FLIP and
sensitizes MPM cells to AT-IAP. We recently reported that
HDAC inhibitors such as SAHA downregulate FLIP(S) and
FLIP(L) expression in colorectal cancer35 and MPM36 cells in
a proteasome-dependent manner. Thus, we assessed
whether SAHA could sensitize MPM cells to SMC treatment.
SAHA treatment triggered downregulation of both FLIP(L)
and FLIP(S) in Ren, MM98 and H28 cells, but not Ju77 cells
(Figure 6a). Notably, in those cell lines in which SAHA
treatment caused downregulation of FLIP, apoptosis induced
by AT-IAP/TNFa was significantly enhanced as assessed by
PARP cleavage (Figure 6a), cell viability assays (Figure 6b
and Supplementary Figure 6) and caspase 3/7 activity
assays (Figure 6c). In contrast, no enhancement of cell
death was observed in Ju77 cells in which FLIP was not
downregulated in response to SAHA (Figures 6a and c and
Supplementary Figure 6). It was also apparent that SAHA
treatment enhanced sensitivity to TNFa alone much more
than to AT-IAP alone (Figure 6b), which is similar to
the results obtained following FLIP silencing described
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Figure 5 (a) Western blot analysis of FLIP(L) and FLIP(S) expression following the treatment of REN, MM98, H28 and JU77 cells for 48 h with 1,5 and 10 mM cisplatin.
(b) Cell viability assays in (i) REN, (ii) MM98, (iii) H28 and (iv) JU77 cells cotreated with 10 mM AT-IAP, 10 ng/ml TNFa or a combination of AT-IAP and TNFa and 1, 5 or 10mM
cisplatin for 48 h
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above. SAHA also enhanced sensitivity of MPM cells to
concentrations of AT-IAP as low as 10 nM and in cells
cotreated with concentrations of TNFa as low as 0.1 ng/ml
(Figure 6d).
As HDAC inhibitors have multiple effects in cells, we
demonstrated that the effects of SAHA on apoptosis induced
by AT-IAP/TNFa was due to FLIP downregulation using
Ren MPM cell lines overexpressing FLIP(L) and FLIP(S)
(Figure 7a).We have previously shown that SAHA is unable to
downregulate exogenous FLIP expression in either of these
two cell line models.36 Consistent with FLIP downregulation
being necessary for SAHA treatment to promote AT-IAP/
TNFa-induced cell death, overexpression of either FLIP(S) or
FLIP(L) blocked the effects of SAHA and AT-IAP/TNFa
cotreatment on cell death (Figure 7b). To directly prove that
combined treatment with SAHA and AT-IAP/TNFa results in
apoptosis induction rather than necroptosis, we cotreated
cells with the pan-caspase inhibitor z-VAD-fmk and the
necroptosis inhibitor Nec-1. z-VAD-fmk, but not Nec-1,
blocked the cytotoxic effects of SAHA and AT-IAP/TNFa
cotreatment indicating that the cell death induced is indeed
apoptotic (Figure 7c). We further defined the mode of
apoptosis induced by SAHA and AT-IAP/TNFa cotreatment
to be caspase eight-dependent using siRNA to downregulate
procaspase eight levels before treatment. In cells in which
procaspase 8 was depleted, the apoptosis induced by SAHA
and AT-IAP/TNFa cotreatment was completely abrogated
(Figure 7d), indicating that the mechanism of cell death is
caspase eight-dependent, consistent with a FLIP-dependent
mechanism (Figure 7b). In further support of this mechanism,
caspase 8 processing to its p43- and p18-forms was detected
in control siRNA transfected, SAHA and AT-IAP/TNFa
cotreated cells (Figure 7d, Western blot, lane 3).
Discussion
An inflammatory microenvironment makes a major
contribution to cancer progression and drug resistance
by promoting tumor cell survival.37 Chronic inflammation
associated with asbestos exposure is strongly linked with
initiation and progression of MPM, and a number of studies
have established important roles for pro-inflammatory
cytokines inMPM tumorigenesis.2,4 Circulating TNFa expression
is significantly elevated in MPM patients and surgical
debulking significantly reduces the levels of circulating TNFa
in patients.4 This is consistent with a substantial TNFa-rich
inflammatory cell component associated with MPM. In this
study, we examined the activity of a novel SMC in preclinical
models of MPM to provide evidence for their clinical
evaluation in this disease. In particular, we focused on the
impact of TNFa on sensitivity to SMCs as we hypothesized
that SMCs could convert this pro-inflammatory cytokine that is
present in the mesothelioma microenvironment into a potent
apoptosis inducing cytokine by downregulating cIAP1 and 2
and, thereby promoting breakdown of the pro-survival TNFR1
Complex I and formation of the pro-apoptotic Complex II.
Thus, the central tenet of our approach was that inhibition of
IAP function would divert microenvironment-derived,
pro-inflammatory signaling from activating pro-tumorigenic
NF-kB-driven responses towards apoptosis-promoting and
anti-inflammatory signaling phenotypes.
Surprisingly, despite expressing all the pro-apoptotic
components of TNFR1 Complex IIb, none of the meso-
thelioma cell lines examined was sensitive to SMCs, either
alone or in combination with TNFa. Moreover, neither TNFa
alone nor SMCalonewas able to promote formation of TNFR1
Complex IIb; only cotreatment with both agents resulted in
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Figure 6 (a) Western blot analysis of PARP cleavage and FLIP expression in MPM cell lines pretreated with 2.5mM SAHA for 12 h before treatment with 10mM AT-IAP,
10 ng/ml TNFa or a combination of AT-IAP and TNFa for 24 h. (b) Cell viability assays in REN cells pretreated with 0.5, 1, 2.5 and 5 mM SAHA for 12 h before treatment with
10mM AT-IAP, 10 ng/ml TNFa or a combination of AT-IAP and TNFa for 48 h. (c) Caspase 3/7 activity assay in MPM cells pretreated with 2.5mM SAHA for 12 h before
treatment with 10mM AT-IAP, 10 ng/ml TNFa or a combination of AT-IAP and TNFa for 24 h. (d) Cell viability assay in REN cells pretreated with 2.5mM SAHA for 12 h before
treatment with combinations of 100 nM or 10 nM AT-IAP with 10, 1, 0.5 or 0.1 ng/ml TNFa for 48 h
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formation of this potentially cell death inducing complex.
However, FLIP was also recruited to this complex in TNFa
and SMC cotreated cells, and using RNAi approaches,
we demonstrated that this recruitment blocked caspase 8
activation and initiation of apoptosis by this complex.
Thus, FLIP is a major mediator of resistance to SMCs in
mesothelioma cells as determined in cocultures with physio-
logically relevant levels of TNFa. Furthermore, we found that
both splice forms were capable of blocking apoptosis
induction in response to TNFa and SMC cotreatment.
Although, TNFR1 complex IIb can induce programmed
necrosis (necroptosis) under certain conditions (for example,
if FLIP(S) is recruited rather than FLIP(L)),28 we found that the
mechanism of cell death induced when either FLIP splice form
was downregulated in TNFa and SMC cotreated meso-
thelioma cells was apoptotic. These results indicate that in
order for SMCs to unleash the pro-apoptotic potential of TNFa,
mesothelioma cells must be cotreated with a FLIP inhibitor.
FLIP is a major antiapoptotic protein that as well as
inhibiting TNFR1 complexes IIa, IIb and the ripoptosome,
also blocks apoptosis induction in response to death ligands
such as FasL and TRAIL and in response to various
chemotherapeutic drugs in vitro and in vivo. As such, FLIP
has been recognized as a potential therapeutic target for a
range of cancers. However, because it lacks enzymatic
activity and because there is a current lack of structural data,
FLIP is a difficult therapeutic target. In addition, FLIP’s
antiapoptotic activity relies on its ability to compete with
procaspase 8 for binding to FADD via its death effector
domains (DEDs); as the DEDs of FLIP and procaspase 8 are
highly similar, any small molecule that blocks the FLIP-FADD
interaction may have the unwanted effect of blocking the
procaspase 8-FADD interaction. Because of these difficulties,
we and others have examined a number of approaches
to targeting FLIP expression.35,36,38–40 Of these, HDAC
inhibitors have the most consistent effects on FLIP expres-
sion, with pan-HDAC inhibitors such as vorinostat (SAHA)
suppressing FLIP expression by both transcriptional and post-
transcriptional mechanisms.35,36 Moreover, we recently
reported that SAHA potently downregulates FLIP expression
in mesothelioma cell lines and three-dimensional spheroid
models.36 In this study, we found that SAHA treatment
downregulated FLIP expression in 3/4 of the mesothelioma
cell lines studied, and this downregulation resulted in
induction of caspase 8-dependent apoptosis in cells cotreated
with TNFa and SMC. In our previous study, we found that
SAHA treatment downregulated FLIP expression in 7/7 cell
lines.36 Thus, SAHA is a potent repressor of FLIP expression
in mesothelioma and is significantly more effective in this
regard than the current standard-of-care, cisplatin. We there-
fore conclude that cotreatment with SAHA (or a similar HDAC
inhibitor) and a SMC could be a promising therapeutic
approach for the treatment of mesothelioma that will exploit
the TNFa-rich, pro-inflammatory micro-environment to induce
apoptosis via TNFR1 complex IIb (Figure 8). Moreover,
circulating levels of TNFa would be a candidate biomarker for
sensitivity to this novel combination treatment that could be
assessed routinely through non-invasive means.
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Figure 7 (a) Western blot analysis of FLIP expressing in control (EV) REN cells and cells stably overexpressing FLIP(S) (FS) and FLIP(L) (FL). (b) Cell viability assay of
REN EV, FS and FL overexpressing cell lines pretreated with 2.5mM SAHA for 12 h before treatment with 10mM AT-IAP, 10 ng/ml TNFa or a combination of AT-IAP and TNFa
for 48 h. (c) Cell viability assay of REN cells pretreated with 2.5mM SAHA for 12 h before treatment with 10 mM AT-IAP, 10 ng/ml TNFa or a combination of AT-IAP and
TNFa for 48 h. Cells were incubated with 10 mM z-VAD-fmk (Z-VAD) or 30mM necrostatin-1 (NEC-1) for 1 h before treatment with AT-IAP and TNFa. (d) (i) Cell viability assay
of REN cells transfected with SCRsi or caspase 8 (C8si). Cells were pretreated with 2.5mM SAHA for 12 h before treatment with 10mM AT-IAP, 10 ng/ml TNFa or a
combination of AT-IAP and TNFa for 48. (ii) Western blot analysis of caspase 8 expression in REN cells transfected with SCRsi or caspase 8 (C8si) siRNA. Cells were
pretreated with 2.5mM SAHA for 12 h before treatment with 10mM AT-IAP and 10 ng/ml TNFa combination for 48 h
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Materials and Methods
Compounds. AT-IAP was supplied by Astex Pharmaceuticals
(Cambridge, UK). SAHA was obtained from Selleck Chemicals (Houston, TX,
USA). Z-VAD-fmk and nec-1 were purchased from Calbiochem (Gibbstown,
NJ, USA). Cisplatin was obtained from Belfast City Hospital (Hospira, UK).
Recombinant TNFa was purchased from Prospec (Rehovot, Israel).
Western blotting. Western blotting was carried out as previously described.41
cIAP2, XIAP and caspase 3 specific antibodies were from Cell Signaling
Technology (Danvers, MA, USA). FLIP and caspase 8 antibodies were from Alexis
Biochemicals (San Diego, CA, USA). PARP antibody was from eBioscience
(San Diego, CA). cIAP1 was from Enzo (Exeter, UK). RIPK1 and FADD were
obtained from BD Transduction Laboratories (Franklin Lakes, NJ, USA).
Secondary horseradish peroxidase-conjugated antibodies (Amersham,
Buckinghamshire, UK) were used for detection.
Cell lines. REN cell line was donated by Prof. Steven M. Albelda, University of
Pennslyvania Medical center, Philadelphia, USA. MM98 cell line was a kind gift
from Dr Stefano Biffo from San Raffaele Scientific Institute, Milan, Italy. NCI-H28
and JU77 cells were donated by Dr. Peter Szlosarek from Queen Mary University
of London. NCI-H28, JU77 and MM98 cells were maintained in RPMI medium
(Invitrogen, Paisley, UK) supplemented with 10% fetal bovine serum (Invitrogen).
REN cells were maintained in F-12 (Hams) medium (Invitrogen) and
supplemented with 10% fetal bovine serum (Invitrogen).
Generation of overexpressing cell lines. REN cell lines overexpres-
sing FLIP(L) and FLIP(S) were generated as previously described.36
Flow cytometry. Samples were analyzed on a BD FACS Calibur flow
cytometer. Cell surface TNFR1 expression was assessed following live cell
staining with Phycoerythrin-conjugated TNFR1 antibody, purchased from R & D
Systems (Minneapolis, MN). All experiments were carried out with an isotype
control antibody. Sub G0/G1 populations were determined using propidium iodide
staining (Sigma-Aldrich, Gillingham, UK) as previously described.41
siRNA transfections. Scrambled control (SCR), c-FLIP and XIAP targeting
siRNAs were obtained from Dharmacon (Chicago, IL, USA). cIAP1, cIAP2, FADD
and caspase 8 were purchased from Qiagen (Crawley, UK). siRNA transfections
were carried out using Oligofectamine (Invitrogen) as previously described.41
Quantitative PCR. RNA was extracted using RNA STAT-60 (Tel-Test Inc.,
Friendswood, TX, USA) according to the manufacturer’s instructions. cDNA was
synthesized using Transcriptor First Strand cDNA synthesis kit (Roche, Burgess
Hill, UK) according to the manufacturer’s instructions. Quantitative PCR was
carried out on LC480 using Syber green (Roche) according to the manufacturer’s
instructions. Primer sequences: c-FLIP(L): F: CCT AGG AATCTGCGTGATAATC
GA R:TGGGATATACCATGCATACTGAGATG, c-FLIP(S): F:ATTTCCAAGAATTT
TCAGATCAGGA R:GCAGCAATCCAAAAGAGTCTCA, TNFa: F:CAGCCTCTTCT
CCTTCCTGAT, R:GCCAGAGGGCTGATTAGAGA, cIAP1: F: AGAAAATGCTGAC
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Figure 8 Schematic diagram summarizing the key findings. (a) Recruitment of cIAP to TNFR1 following binding by TNFa is mediated by TRADD and TRAF2 and results in
RIPK1 ubiquitination, which then promotes activation of pro-survival NFkB signaling (via the LUBAC/IKK signalling complexes) and activation of the MAPK pathway (via the
TAB/TAK complex). (b) In the presence of SMCs, cIAPs are polyubiquitinated and degraded by the proteasome, and RIPK1 is recruited to a second complex (Complex IIb)
where it recruits FADD, FLIP and procaspase 8. SMCs can also block XIAP-mediated inhibition of caspases 3, 7 and 9. If present in sufficient amounts, FLIP will inhibit
activation of caspase 8 at Complex IIb and thereby limit the activation of the downstream executioner caspases 3 and 7 with the result that the cells survive. (c) HDAC inhibitors
such as SAHA efficiently target FLIP for degradation via the proteasome. Thus, when cells are cotreated with SAHA and SMC, procaspase 8 homodimers are recruited to
Complex IIb, resulting in caspase 8 activation and subsequent activation of the executioner caspases and induction of apoptosis. The activation of the executioner caspases is
further facilitated by SMC-mediated inhibition of XIAP
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CCACCA R: GGTGTATTCATCATGACAGCATCt, cIAP2: F:GACTGGGCTTGTCC
TTGCT, R:AAGAAGTCGTTTTCCTCCTTTGT, XIAP: F: TTTTGGGACATGGATAT
ACTCAGTT, R:GCACTTTACTTTATCACCTTCACCT.
Immunoprecipitation. Cells were lysed in CHAPS buffer (30 mM Tris
pH 7.5, 150 mM NaCl, 1% CHAPS). One microgram of capsase-8 p18 antibody
(Santa Cruz, CA, USA) was conjugated to 30 ml Protein G Dynabeads (Invitrogen).
Seven-hundred and fifty microgram of protein lysate was immunoprecipitated for
6 h at 4 1C. IgG isoytpe controls were purchased from Dako Cytomation
(Cambrideshire, UK). Coimmunoprecipitation experiments were analyzed by
western blotting.
Caspase 3/7 activity assays. Caspase 3/7 activity was assayed using
Caspase-Glo 3/7 assay system (Promega, Madison, WI).
Cell viability assay. Cell viability was assessed by 3-(4,5–dimethylthiazol–
2–yl)-2,5-diphenyltetrazolium bromide (MTT, Sigma) assay as described
previously.41
AlphaScreen. AlphaScreen assay was carried out using the anti-FLAG
acceptor and GSH donor beads of the ALPHA (Amplified Luminescent Proximity
Homogenous Assay) technology (Perkin Elmer, Waltham, MA, USA).
FLAG-tagged FLIP(S)WT or F114A mutant were expressed in HCT116 cells
and cell lysates generated using CHAPS buffer. Recombinant GST-FADD was
expressed in BL21 bacteria and purified. The assay was conducted in PBS in a
total reaction volume of 50ml. Two microgram of the FLAG-FLIP(S) containing
lysate was incubated with 0.5mg of GST-FADD for 45 min, following the addition of
acceptor beads and donor beads, both to the final concentration of 10 mg/ml. The
assay was then read on a luminometer.
Statistical analysis. Experimental results were compared using a two-tailed
Students t-test, *Po0.05, **Po0.01 and ***Po0.001.
Conflict of Interest
Prof. Fennell has worked as a consultant for Merck, who manufacture
Vorinostat. Drs. Gianni Chessari and George Ward are full-time
employees of Astex Pharmaceuticals who manufacture the SMAC mimetic
AT-IAP used in this study. All other authors declare no conflict of interest.
Acknowledgements. NC and IS were supported by grants from the British
Lung Foundation. CH was supported by CRUK.
1. Hodgson JT, McElvenny DM, Darnton AJ, Price MJ, Peto J. The expected burden of
mesothelioma mortality in Great Britain from 2002 to 2050. Br J Cancer 2005; 92:
587–593.
2. Choe N, Tanaka S, Xia W, Hemenway DR, Roggli VL, Kagan E. Pleural macrophage
recruitment and activation in asbestos-induced pleural injury. Environ Health Perspect
1997; 105(Suppl 5): 1257–1260.
3. Li Q, Wang W, Yamada T, Matsumoto K, Sakai K, Bando Y et al. Pleural mesothelioma
instigates tumor-associated fibroblasts to promote progression via a malignant cytokine
network. Am J Pathol 2011; 179: 1483–1493.
4. Gordon GJ, Mani M, Mukhopadhyay L, Dong L, Yeap BY, Sugarbaker DJ et al. Inhibitor of
apoptosis proteins are regulated by tumour necrosis factor-alpha in malignant pleural
mesothelioma. J Pathol 2007; 211: 439–446.
5. Partanen R, Koskinen H, Hemminki K. Tumour necrosis factor-alpha (TNF-alpha) in
patients who have asbestosis and develop cancer. Occup Environ Med 1995; 52: 316–319.
6. Villanova F, Procopio A, Rippo MR. Malignant mesothelioma resistance to apoptosis:
recent discoveries and their implication for effective therapeutic strategies. Curr Med Chem
2008; 15: 631–641.
7. Fennell DA, Rudd RM. Defective core-apoptosis signalling in diffuse malignant
pleural mesothelioma: opportunities for effective drug development. Lancet Oncol 2004;
5: 354–362.
8. Zaffaroni N, Costa A, Pennati M, De Marco C, Affini E, Madeo M et al. Survivin is highly
expressed and promotes cell survival in malignant peritoneal mesothelioma. Cell Oncol
2007; 29: 453–466.
9. Kleinberg L, Lie AK, Florenes VA, Nesland JM, Davidson B. Expression of inhibitor-
of-apoptosis protein family members in malignant mesothelioma. Hum Pathol 2007; 38:
986–994.
10. Gordon GJ, Mani M, Mukhopadhyay L, Dong L, Edenfield HR, Glickman JN et al.
Expression patterns of inhibitor of apoptosis proteins in malignant pleural mesothelioma.
J Pathol 2007; 211: 447–454.
11. Deveraux QL, Reed JC. IAP family proteins–suppressors of apoptosis. Genes Dev 1999;
13: 239–252.
12. Vaux DL, Silke J. IAPs, RINGs and ubiquitylation. Nat Rev Mol Cell Biol 2005; 6: 287–297.
13. Suzuki Y, Nakabayashi Y, Takahashi R. Ubiquitin-protein ligase activity of X-linked inhibitor
of apoptosis protein promotes proteasomal degradation of caspase-3 and enhances
its anti-apoptotic effect in Fas-induced cell death. Proc Natl Acad Sci USA 2001; 98:
8662–8667.
14. Deveraux QL, Leo E, Stennicke HR, Welsh K, Salvesen GS, Reed JC. Cleavage of human
inhibitor of apoptosis protein XIAP results in fragments with distinct specificities for
caspases. EMBO J 1999; 18: 5242–5251.
15. Scott FL, Denault JB, Riedl SJ, Shin H, Renatus M, Salvesen GS. XIAP inhibits caspase-3
and -7 using two binding sites: evolutionarily conserved mechanism of IAPs. EMBO J 2005;
24: 645–655.
16. Rothe M, Pan MG, Henzel WJ, Ayres TM, Goeddel DV. The TNFR2-TRAF signaling
complex contains two novel proteins related to baculoviral inhibitor of apoptosis proteins.
Cell 1995; 83: 1243–1252.
17. Mahoney DJ, Cheung HH, Mrad RL, Plenchette S, Simard C, Enwere E et al. Both cIAP1
and cIAP2 regulate TNFalpha-mediated NF-kappaB activation. Proc Natl Acad Sci USA
2008; 105: 11778–11783.
18. Bertrand MJ, Milutinovic S, Dickson KM, Ho WC, Boudreault A, Durkin J et al. cIAP1 and
cIAP2 facilitate cancer cell survival by functioning as E3 ligases that promote RIP1
ubiquitination. Mol Cell 2008; 30: 689–700.
19. Micheau O, Tschopp J. Induction of TNF receptor I-mediated apoptosis via two sequential
signaling complexes. Cell 2003; 114: 181–190.
20. Micheau O, Lens S, Gaide O, Alevizopoulos K, Tschopp J. NF-kappaB signals induce the
expression of c-FLIP. Mol Cell Biol 2001; 21: 5299–5305.
21. He S, Wang L, Miao L, Wang T, Du F, Zhao L et al. Receptor interacting protein kinase-3
determines cellular necrotic response to TNF-alpha. Cell 2009; 137: 1100–1111.
22. Du C, Fang M, Li Y, Li L, Wang X. Smac, a mitochondrial protein that promotes
cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell 2000; 102:
33–42.
23. Feltham R, Bettjeman B, Budhidarmo R, Mace PD, Shirley S, Condon SM et al. Smac
mimetics activate the E3 ligase activity of cIAP1 protein by promoting RING domain
dimerization. J Biol Chem 2011; 286: 17015–17028.
24. Varfolomeev E, Blankenship JW, Wayson SM, Fedorova AV, Kayagaki N, Garg P et al.
IAP antagonists induce autoubiquitination of c-IAPs, NF-kappaB activation, and TNFalpha-
dependent apoptosis. Cell 2007; 131: 669–681.
25. Petersen SL, Wang L, Yalcin-Chin A, Li L, Peyton M, Minna J et al. Autocrine TNFalpha
signaling renders human cancer cells susceptible to Smac-mimetic-induced apoptosis.
Cancer Cell 2007; 12: 445–456.
26. Chessari G, Buck I, Chiarparin E, Day J, Frederickson M, Criffiths-Jones C et al. Ann Oncol
2012; 24–24.
27. Darding M, Feltham R, Tenev T, Bianchi K, Benetatos C, Silke J et al. Molecular
determinants of Smac mimetic induced degradation of cIAP1 and cIAP2. Cell Death Differ
2011; 18: 1376–1386.
28. Feoktistova M, Geserick P, Kellert B, Dimitrova DP, Langlais C, Hupe M et al. cIAPs block
Ripoptosome formation, a RIP1/caspase-8 containing intracellular cell death complex
differentially regulated by cFLIP isoforms. Mol Cell 2011; 43: 449–463.
29. Wang L, Du F, Wang X. TNF-alpha induces two distinct caspase-8 activation pathways.
Cell 2008; 133: 693–703.
30. Tenev T, Bianchi K, Darding M, Broemer M, Langlais C, Wallberg F et al. The
Ripoptosome, a signaling platform that assembles in response to genotoxic stress and loss
of IAPs. Mol Cell 2011; 43: 432–448.
31. Krueger A, Schmitz I, Baumann S, Krammer PH, Kirchhoff S. Cellular FLICE-inhibitory
protein splice variants inhibit different steps of caspase-8 activation at the CD95 death-
inducing signaling complex. J Biol Chem 2001; 276: 20633–20640.
32. Ueffing N, Keil E, Freund C, Kuhne R, Schulze-Osthoff K, Schmitz I. Mutational analyses of
c-FLIPR, the only murine short FLIP isoform, reveal requirements for DISC recruitment.
Cell Death Differ 2008; 15: 773–782.
33. Kinoshita H, Yoshikawa H, Shiiki K, Hamada Y, Nakajima Y, Tasaka K. Cisplatin (CDDP)
sensitizes human osteosarcoma cell to Fas/CD95-mediated apoptosis by down-regulating
FLIP-L expression. Int J Cancer 2000; 88: 986–991.
34. Song JH, Song DK, Herlyn M, Petruk KC, Hao C. Cisplatin down-regulation of cellular Fas-
associated death domain-like interleukin-1beta-converting enzyme-like inhibitory proteins
to restore tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in
human melanoma cells. Clin Cancer Res 2003; 9: 4255–4266.
35. Kerr E, Holohan C, McLaughlin KM, Majkut J, Dolan S, Redmond K et al. Identification of
an acetylation-dependant Ku70/FLIP complex that regulates FLIP expression and HDAC
inhibitor-induced apoptosis. Cell Death Differ 2012; 19: 1317–1327.
36. Hurwitz JL, Stasik I, Kerr EM, Holohan C, Redmond KM, McLaughlin KM et al. Vorinostat/
SAHA-induced apoptosis in malignant mesothelioma is FLIP/caspase 8-dependent and
HR23B-independent. Eur J Cancer 2012; 48: 1096–1107.
37. Wilson C, Purcell C, Seaton A, Oladipo O, Maxwell PJ, O’Sullivan JM et al. Chemotherapy-
induced CXC-chemokine/CXC-chemokine receptor signaling in metastatic prostate cancer
SAHA overcomes FLIP-mediated inhibition of SMCs
N Crawford et al
10
Cell Death and Disease
cells confers resistance to oxaliplatin through potentiation of nuclear
factor-kappaB transcription and evasion of apoptosis. J Pharmacol Exp Ther 2008; 327:
746–759.
38. Logan AE, Wilson TR, Fenning C, Cummins R, Kay E, Johnston PG et al. In vitro and
in vivo characterisation of a novel c-FLIP-targeted antisense phosphorothioate
oligonucleotide. Apoptosis 2010; 15: 1435–1443.
39. Panner A, James CD, Berger MS, Pieper RO. mTOR controls FLIPS translation and TRAIL
sensitivity in glioblastoma multiforme cells. Mol Cell Biol 2005; 25: 8809–8823.
40. Wilson TR, McLaughlin KM, McEwan M, Sakai H, Rogers KM, Redmond KM et al.
c-FLIP: a key regulator of colorectal cancer cell death. Cancer Res 2007; 67:
5754–5762.
41. Longley DB, Wilson TR, McEwan M, Allen WL, McDermott U, Galligan L et al.
c-FLIP inhibits chemotherapy-induced colorectal cancer cell death. Oncogene 2006; 25:
838–848.
Cell Death and Disease is an open-access journal
published by Nature Publishing Group. This work is
licensed under a Creative Commons Attribution-NonCommercial-
NoDerivs 3.0 Unported License. To view a copy of this license, visit
http://creativecommons.org/licenses/by-nc-nd/3.0/
Supplementary Information accompanies this paper on Cell Death and Disease website (http://www.nature.com/cddis)
SAHA overcomes FLIP-mediated inhibition of SMCs
N Crawford et al
11
Cell Death and Disease
